Patients were categorized according to baseline disease severity using MMSE score: mild (21-26), moderate (15-20), moderately severe/severe (< 15). Costs associated with patient and caregiver health care, patient social care and informal care were evaluated using information from the Resource Use in Dementia instrument (RUD) and the data collection form. The primary objective was the estimation of total cost over the 18 months period. Total cost was estimated by applying country-specific unit costs. Supervision time and caregiver medical costs were excluded from the base case analysis. Imputation methods were used for missing cost data. Results: 419 patients were enrolled (2010)(2011) in 33 centers in France, 289 (69%) remained in the study at 18 months. Reasons for discontinuation were subject institutionalization (n= 65), death (n= 21) or other reason (n= 44). Total mean cumulative costs over the 18-month period were estimated to be respectively 24140€ (21561-26863), 34287€ (30357-38939) and 44171€ (40050-48755) for mild, moderate and moderately severe/ severe patients (p< 0.001) with caregiver informal care cost accounting for approximately half of the total costs (52%, 53%, 51% respectively) (excluding supervision time). Mean overall monthly caregiver time increased over the 18-month period in each severity group, mainly driven by supervision time without significant difference between severity groups in terms of change from baseline. ConClusions: This longitudinal study showed that costs increase with AD severity. Informal care cost represents the largest part of total societal cost at each intermediate time point.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.